Home » Stocks » PCSA

Processa Pharmaceuticals, Inc. (PCSA)

Stock Price: $6.87 USD 0.14 (2.08%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $6.88 +0.01 (0.15%) Jun 11, 5:21 PM
Market Cap 106.63M
Revenue (ttm) n/a
Net Income (ttm) -15.64M
Shares Out 15.52M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $6.87
Previous Close $6.73
Change ($) 0.14
Change (%) 2.08%
Day's Open 6.90
Day's Range 6.65 - 6.99
Day's Volume 85,265
52-Week Range 3.40 - 14.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the...

5 days ago - GlobeNewsWire

HANOVER, MD, June 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the...

6 days ago - GlobeNewsWire

HANOVER, MD, May 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the ...

2 weeks ago - GlobeNewsWire

~ Processa's trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica . Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562 .~

3 weeks ago - GlobeNewsWire

Clinical drug pipeline is funded and targeting major milestones in Q2 and 2H 2021

1 month ago - GlobeNewsWire

HANOVER, MD., May 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the...

1 month ago - GlobeNewsWire

Clinical drug pipeline is funded and targeting major milestones in 2021

2 months ago - GlobeNewsWire

HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve t...

2 months ago - GlobeNewsWire

HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical con...

2 months ago - GlobeNewsWire

HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and accredi...

3 months ago - GlobeNewsWire

Dover, Delaware--(Newsfile Corp. - February 22, 2021) - Encode Ideas, L.P. Initiates Research on Processa Pharmaceuticals, Inc. (NASDAQ: PCSA). The full research publication is available here and availa...

3 months ago - Newsfile Corp

Experienced management team with colossal past exits running 3 active mid-stage clinical programs with enough funding to generate progress through multiple value-inflection points. PCS499: Ulcerative Ne...

4 months ago - Seeking Alpha

HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve th...

5 months ago - GlobeNewsWire

About PCSA

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS64... [Read more...]

Industry
Biotechnology
Founded
2011
Stock Exchange
NASDAQ
Ticker Symbol
PCSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for PCSA stock is "Strong Buy." The 12-month stock price forecast is 17.00, which is an increase of 147.45% from the latest price.

Price Target
$17.00
(147.45% upside)
Analyst Consensus: Strong Buy